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The immune response plays a key role in enhancing
the therapeutic activity of oncolytic virotherapies.
However, to date, investigators have relied on
inherent interactions between the virus and the im-
mune system, often coupled to the expression of a
single cytokine transgene. Recently, the importance
of TLR activation in mediating adaptive immunity
has been demonstrated. We therefore sought to
influence the type and level of immune response
raised after oncolytic vaccinia therapy through
manipulation of TLR signaling. Vaccinia naturally ac-
tivates TLR2, associated with an antibody response,
whereas a CTL response is associated with TLR3-
TRIF-signaling pathways. We manipulated TLR
signaling by vaccinia through deglycosylation of the
viral particle to block TLR2 activation and expression
of a TRIF transgene. The resulting vector displayed
greatly reduced production of anti-viral neutralizing
antibody as well as an increased anti-tumor CTL
response. Delivery in both naive and pre-treated
mice was enhanced and immunotherapeutic activity
dramatically improved.
INTRODUCTION
Viral vectors engineered to display tumor selectivity in their repli-
cation were first tested clinically as cancer therapies almost 20
years ago (Kirn et al., 1997, 1998; Ganly et al., 2000; Khuri
et al., 2000), and although clinical responses were reported, it
has become clear that directly lytic viral replication is rarely suf-
ficient to eradicate large tumors or metastatic disease. More
recently, the combination of faster-replicating vectors and
expression of cytokine (granulocyte macrophage colony-stimu-
lating factor [GM-CSF]) transgenes have resulted in improved
clinical responses (Schmidt, 2011; Park et al., 2008; Heo et al.,
2013; Andtbacka et al., 2013), and the very real potential for
oncolytic viral therapies to effectively treat cancer patients in
the clinic has become apparent. These clinical advances high-264 Cell Reports 15, 264–273, April 12, 2016 ª2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://lighted the critical role the immune response can play in the
successful application of this platform. Tumor-selective viral
replication leads to localized acute inflammation, helps direct
the immune response toward the tumor, and transiently over-
comes tumor-mediated immunosuppression. Meanwhile, lysis
of tumor cells releases relevant tumor antigens and associated
danger molecules, resulting in priming of anti-tumor immunity
and in situ vaccination. However, to date, this immunothera-
peutic activity has relied on the viral vector’s naturally evolved in-
teractions with the host immune response, often boosted by the
expression of a single cytokine transgene.
Concurrent advances in the development of tumor vaccines
have elucidated the advantages of a robust cytolytic T-lympho-
cyte (CTL) response in the successful treatment of cancer
(Okada et al., 2011; June, 2007; Porter et al., 2011; Rosenberg,
2011; Rosenberg et al., 2011). In particular, adjuvant use of
certain TLR ligands such as PolyI:C (Zhu et al., 2010; Trumpfhel-
ler et al., 2008), which binds TLR3 and activates MyD88-inde-
pendent signaling pathways, have been found to result in
production of increased numbers of CTLs.
Vaccinia virus forms the basis of several of themost-promising
oncolytic viral therapies currently in the clinic and has been
shown to naturally activate TLR2 as the earliest step in the im-
mune response post-systemic delivery. Infection in TLR2/
mice resulted in significant reduction in subsequent levels of
circulating anti-viral neutralizing antibody (O’Gorman et al.,
2010). Because anti-viral neutralizing antibody limits the spread
and systemic delivery of oncolytic viral therapies, we sought to
ablate this interaction. TLR2 is a cell-surface receptor, meaning
that viral binding to TLR2 occurs prior to infection of the target
cell, and so prevention of binding to this receptor required an
approach involving modification of the viral particle itself.
In order to reinforce this effect, and to further switch the type of
immune response elicited after oncolytic virus (OV) therapy to-
ward the potentially more-beneficial Th1 arm, we concurrently
enhanced activation of TRIF-mediated signaling pathways
downstream of TLR3. Vectors engineered to both reduce TLR2
binding and to enhance TRIF signaling displayed a robust switch
in the type of adaptive immune response produced, with a signif-
icantly reduced humoral response and enhanced CTL response,
as well as showing greatly enhanced therapeutic activity. The ef-
fects of altering activation profiles of TLR-signaling pathways oncreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Deglycosylation of Vaccinia Virus
Envelope
(A) Immunoblot showing deglycosylation of
vaccinia virus envelope protein B5R. Purified WR
(wild-type strain WR) and dgWR (deglycosylated)
viruses were disrupted and blotted using an anti-
B5R antibody. Decrease in protein weight corre-
sponds to deglycosylation of the B5R protein.
(B) Deglycosylation of virus envelope has no effect
on vaccinia virus infectivity. Different mouse tumor
cell lines were infected with TK (strain WR with a
deletion of the viral thymidine kinase gene) or its
deglycosylated version at an MOI of 1, and viral
luciferase expression was measured 3 hr after
infection by bioluminescence imaging. Mean
values + SD of three independent experiments are
plotted.
(C) Deglycosylation reduces TLR2 activation
in vitro. 293 cells expressing mouse TLR2 were
transfected with pNiFty (TLR-signaling reporter
plasmid). Twenty-four hours after transfection,
cells were infected at an MOI of 1 with WR or
dgWR, and TLR2 activation was quantified 24 hr
after infection by bioluminescence imaging.
Means + SD of two independent experiments
(performed in quadruplicate) are depicted.
(D) STAT3 phosphorylation is depleted in splenic
lymphocytes of mice injected with deglycosylated
vaccinia. C57/BL6 mice were injected intrave-
nously with 1 3 107 plaque-forming units (PFUs) of
WR or dgWR, and 1 hr after injection, spleens were
excised, dissociated, and prepared for intracellular
analysis. Percentage of pSTAT1pSTAT3+ lym-
phocytes was determined by flow cytometry. PBS
and PAM(3)CSK(4) were used as controls. Values
of individual mice andmeans ± SEM of the different
treatments are plotted.
(E) Deglycosylation of vaccinia virus (TK) enve-
lope selectively increases viral gene expression
from tumors in vivo. Balb/c mice harboring subcutaneous tumors of Renca cells (mouse renal adenocarcinoma) were randomized and injected with a single
intravenous dose of 13 108 PFUs per mouse of TK or dgTK (both expressing firefly luciferase). Kinetics of viral gene expression from within the tumor (left) or
for the upper body (lungs, spleen, and liver signal; right) was monitored by bioluminescence imaging of viral luciferase expression. Mean values of 12 or 13
animals + SD are plotted. *p < 0.05 compared with PBS or control; #p < 0.05 compared with TK or WR group; fp < 0.05 compared with PAM(3)CSK(4) group.the induction of anti-tumor CTL and anti-viral neutralizing anti-
body were explored along with the additional beneficial effects
on viral systemic delivery to the tumor in single- or repeat-deliv-
ery regimens.
RESULTS
Reduction of Vaccinia Binding to TLR2
In initial experiments, we looked to reduce or ablate vaccinia
binding to TLR2 in order to reduce MyD88 signaling that we
had previously associated with induction of anti-viral neutralizing
antibody. It was determined that multiple vaccinia surface pro-
teins were capable of binding and activating this receptor, either
as a TLR2 homodimer or a TLR2:6 heterodimer (Figure S1), mak-
ing genetic modification of the virus complex. Instead, because
TLR2 ligands are primarily glycoproteins, we looked to treat the
viral particle itself with a mix of deglycosylating enzymes in order
to cleave sugars from the viral surface. Successful deglycosyla-
tion was confirmed through immunoblot analysis of the viral B5Rprotein (Figures 1A and S2A). Interestingly, there was no loss of
infectivity of tumor cell lines after deglycosylation of the viral
particle (Figure 1B; TK represents vaccinia strain WR with a
thymidine kinase deletion and luciferase expression, used as a
model oncolytic virus; dgTK represents deglycosylated TK);
however, activation of pathways downstream of TLR2 binding
were significantly reduced both in vitro (reduced necrosis factor
kB [NF-kB] activation) and in vivo (reduced pSTAT3 levels) as a
result of viral particle deglycosylation (Figures 1C, 1D, and
S2B). Activation was not completely lost, but this was not sur-
prising as MyD88-mediated signaling pathways are common
to most TLRs.
However, of particular interest was the observation that viral
gene expression from the tumor was significantly increased after
systemic delivery of deglycosylated virus in several mouse tumor
models (Figures 1E and S2C), as determined by biolumines-
cence imaging of viral luciferase transgene expression. This in-
crease was evident within 24 hr of systemic delivery and led to
a >10-fold increase in viral gene expression in the tumor byCell Reports 15, 264–273, April 12, 2016 265
Figure 2. Oncolytic Vaccinia Virus Express-
ing the Mouse TRIF Protein Increases Acti-
vation of TLR-Responding Pathways and
the Induction of Necroptosis
(A and B) Activation of NF-kB and IRF3 pathways
after infection with TK-TRIF and TK-DAI. ELISA
assayswere utilized to determine concentrations of
pNF-kB (A) and IRF3 (B) in cytoplasmic and nuclear
extracts, respectively, of Renca, MC38, 4T1, or
MEF cells infected with TK, TK-TRIF, or TK-DAI at
an MOI of 1. Analyses were performed 24 hr after
infection. Data were obtained in quadruplicate from
two independent experiments and are plotted as
fold change versus TK + SD. Dashed lines indi-
cate TK activation level.
(C and D) mTRIF expression increases release of
danger-associated molecular patterns (DAMPs).
ELISA assays were utilized for determining the
release of HMGB1 (C) and Hsp-70 (D) after infec-
tion with TK, TK-TRIF, and TK-DAI viruses at an
MOI of 1. Quantification was performed 24 hr after
infection, and data are depicted as fold change
versus TK + SD, dashed lines indicating TK
release levels.
(E) Percentage of apoptotic cells after infection with
TK-TRIF and TK-DAI. A panel of mouse tumor cell
lines was infected with the indicated viruses using
an MOI of 1. At 48 hr after infection, percentage of
necrotic and apoptotic cells were determined by
flow cytometry by phosphatidylinositol (PI) and
annexin V staining. Two independent experiments
were performed, and means + SD are plotted.day 5 after systemic treatment (relative to TK control virus).
This increase in viral gene expression was restricted to the tu-
mor, with no significant differences seen in bioluminescent signal
from other tissues (Figure 1E). Because there were no differ-
ences in the ability of the deglycosylated virus to infect or repli-
cate in the same tumor cells in vitro (Figure 1B), and because
progeny virus produced after an initial round of replication would
be normally glycosylated, it is assumed that the altered viral gene
expression pattern is mediated by enhanced delivery to the tu-
mor. TLR2-mediated immune activation (STAT3 phosphoryla-
tion) was observed in the majority of cells frommultiple lymphoid
lineages in the spleen within 15 min of systemic delivery of the
virus (O’Gorman et al., 2010). It is likely, therefore, that the reduc-
tion in TLR2 activation as a result of viral deglycosylation (Fig-
ure 1D) can delay the priming of the immune response until after
the initial infection of cells in the tumor, so allowing improved
initial delivery and early viral gene expression, leading to
enhanced subsequent spread within the tumor.
Expression of TRIF to Enhance CTL Induction
In order to complement the effects of reduced MyD88-pathway
signaling, we looked to selectively activate alternate TLR-
signaling pathways. In particular, because binding of ligand to
TLR3, leading to activation of TRIF pathway signaling, results
in the induction of a robust CTL response (Warger et al., 2006;266 Cell Reports 15, 264–273, April 12, 2016Seya and Matsumoto, 2009), the effects of TRIF expression
from vaccinia were examined. Alternatively, DNA-dependent
activator of interferon (DAI) activation is also associated with
increased CTL induction (Takaoka et al., 2007; Wang et al.,
2008), and so the effects of TRIF expression were initially
compared to that of DAI through construction and testing of
tumor-selective viral vectors expressing each of these innate
sensors separately (Figure S3). In initial experiments comparing
the effects of TRIF or DAI expression in vitro (Figures 2A, 2B, and
S4), both transgenes were found to increase NF-kB activation
(Figure 2A), activation of type I interferon (IFN)-signaling path-
ways (IRF3 expression; Figure 2B), and release of selected cyto-
kines and chemokines relative to our control virus (TK;
Figure S4). However, in all these assays and for multiple cell lines
tested, TRIF expression consistently resulted in more-robust
innate immune activation than DAI expression. This may be
due to vaccinia’s inherent activation of the cytoplasmic DNA
sensor DAI with limited natural activation of the double-stranded
RNA (dsRNA) sensor TLR3.
When TK and TK-TRIF vectors were compared head to head
in vivo through systemic treatment of immunocompetent mice
bearing subcutaneous renal cancer (Renca) tumors (Figure 3A),
TRIF expression again resulted in increased cytokine and che-
mokine production within the tumor. However, in vivo, there
was a marked preference for enhanced expression of cytokines
Figure 3. In Vivo Effects of TRIF Expression
(A) In vivo intratumoral concentration of cytokines
and chemokines. Balb/c mice with established
Renca subcutaneous tumors were randomized
and injected with a single intravenous dose of
1 3 108 PFUs per mouse of TK or TK-TRIF. Four
days after injection, tumors were harvested and
concentrations of selected cytokines and chemo-
kines were determined in tumor lysates by
Luminex or ELISA assays. Fold change versus
TK from four to five mice per group + SD is
plotted. Dashed line indicates TK concentra-
tions. *p < 0.05 compared with TK group;
#p < 0.05 compared with TK-DAI group.
(B) Anti-tumor activity of TK-TRIF and TK-DAI.
Renca or MC38 cells were implanted in Balb/c or
C57/Bl6 mice, respectively, and mice were in-
jected with PBS or 13 108 PFUs of TK, TK-TRIF,
or TK-DAI through the tail vein. Tumor volumes
were measured at indicated time points. n = 12–15
mice/group + SE. *p < 0.05 compared with PBS
group; #p < 0.05 compared with TK group; f p <
0.05 compared with TK-DAI group.involved in the Th1 response (IFN-g, interleukin-12 [IL-12], and
IFN-g inducible protein 10 [IP-10]) after treatment with TK-
TRIF, whereas no such increases were seen in the level of induc-
tion of Th2-associated cytokines (IL-4 and IL-5; N.B. IL-6 was
below the limits of detection in vivo; Figure 3A). This is in contrast
to the cytokine profile produced after infection of Renca cells
in vitro, where the Th2 cytokine IL-6 predominated. It is possible
that the altered cytokine profiles seen in vitro and in vivo may be
at least in part mediated by fibroblasts and other non-tumor cells
in the tumor, as murine embryonic fibroblasts (MEFs) in vitro dis-
played a different profile of cytokine release compared to tumor
cell lines with selective increases in IFN-b production (Figure S4).
Our recent publication has demonstrated the critical importance
of tumor-fibroblast cross talk in the effective application of onco-
lytic viral therapies (Ilkow et al., 2015).
Neither TRIF nor DAI expression affected viral replication
in vitro in two of three cell lines tested; however, both TRIF and
DAI reduced viral replication in Renca cells relative to control
virus (TK; Figure S5A). However, despite the reduced viral repli-
cation, there was no loss in the tumor cell killing capacity (Fig-
ure S5B). The reduced viral replication in Renca cells in vitro
was apparently not due to induction of anti-viral immunity, as
TRIF (or DAI) expression had the least effect on the immune
parameters tested in this cell line (Figures 2A, 2B, and S4). How-
ever, a secondary pathway mediated by TRIF acts through RIP3
kinase to induce necroptosis, an immunogenic route of pro-
grammed cell death (Kaiser et al., 2013), so the effects of TRIF
expression on this pathway were also examined. It was seen
that release of known DAMP (danger-associated molecular
pattern) molecules (HMGB-1 and Hsp70) were increased in all
of the tumor cell lines when infected with virus expressing
TRIF; however, this only became significant in Renca cells (Fig-ures 2C and 2D). To further support the hypothesis that the
reduced viral replication of TK-TRIF in Renca cells was due to
increased immunogenic cell death, we examined the percentage
of annexin V+ cells after infection (Figure 2E). It was seen that
either TRIF or DAI expression significantly increased the level
of annexin V staining in Renca cells. There was also a significant
increase in 4T1 cells, but the overall increase was not as dra-
matic, and there was no effect in MC38 cells. Increased necrop-
tosis and release of DAMPs in Renca cells was therefore coupled
to reduce viral replication in vitro.
The anti-tumor effects of TK-TRIF and TK-DAI were also
compared to TK in vivo following systemic delivery of a single
dose to two syngeneic mouse tumor models: BALB/c mice
bearing Renca tumors or C57/BL6 mice bearing MC38 tumors
(Figures 3B and 4A). It was observed that viral gene expression
from within the tumor (as determined by bioluminescence imag-
ing of viral luciferase transgene expression) was decreased in
both tumormodelswhenTRIF orDAIwere expressed (Figure 4A).
This is unsurprising, as TRIF and DAI both enhance immune in-
duction mediated by viral infection of these cell lines in vitro (Fig-
ures 2A, 2B, and S4). TRIF expression was also found to increase
the levels of many Th1-associated cytokines in Renca tumors
in vivo (Figure 4B) and was further found to increase the infiltra-
tion of both CD3+CD4+ and CD3+CD8+ cells into Renca tumors
in vivo (Figure 4C). As such, TRIF expression reduces viral repli-
cation in the tumor but enhances immune activation.
Despite the observed reduction in viral gene expression, both
TK-TRIF and TK-DAI significantly increased the anti-tumor effect
of oncolytic vaccinia therapy (relative to TK) in Renca or MC38-
tumor-bearing mice (Figure 3B). This increased therapeutic
effect again demonstrates the advantage of enhancing the
immunotherapeutic activity of oncolytic virus strains, even ifCell Reports 15, 264–273, April 12, 2016 267
Figure 4. In Vivo Immunotherapeutic Effects
of TRIF Expression
(A) Viral gene expression in vivo. Renca or MC38
cells were implanted in Balb/c or C57/Bl6 mice,
respectively, and mice were injected with PBS or
1 3 108 PFUs of TK, TK-TRIF, or TK-DAI through
the tail vein. Viral luciferase expression from
within the tumors was measured at indicated time
points. n = 12–15 mice/group + SE. *, significant
p < 0.05 compared with PBS group; #, significant
p < 0.05 compared with TK group; f, signifi-
cant p < 0.05 compared with TK-DAI group.
(B) Altered T cell repertoire in the tumor after TK or
TK-TRIF injection. Balb/c mice with subcutaneous
Renca tumors were treated with a single intrave-
nous injection of PBS or 1 3 108 PFUs/mouse
of indicated viruses, and tumors were harvested
at day 7 post-virus injection and evaluated
for lymphocyte populations by flow cytometry.
Percentages of (left) CD3+CD4+ and (right)
CD3+CD8+ populations are plotted.
(C) TK-TRIF improves the anti-tumor efficacy
compared to TK-GMCSF in a mammary semi-
orthotopic model. 4T1 cells were implanted in the
mammary fat pad of Balb/c mice, and once the
tumor was established, mice were injected with
PBS or 1 3 108 PFUs of TK, TK-TRIF, or TK-
GMCSF through the tail vein. (Left) Tumor volumes
and (right) viral luciferase expression from within
the tumorsweremeasured at indicated time points.
n = 12–14 mice/group + SE.this leads to a reduction in viral replication. In a further mouse tu-
mor model (orthotopically implanted 4T1 breast cancer; Fig-
ure 4C), TK-TRIF was compared to TK-mGMCSF (as a mouse
equivalent of the clinical JX-594 [Pexa-Vec] viral therapy [Park
et al., 2008; Heo et al., 2013]; Jennerex, now part of Silajen)
and again demonstrated significantly improved therapeutic ef-
fects, despite a reduction in viral gene expression from the tumor
(Figure 4C). Of note, in all in vivo experiments, a single intrave-
nous dose of 1 3 108 plaque-forming units (PFUs) was used, a
log lower than the dose we have traditionally used. This reduced
dose was used to deliberately limit therapeutic activity in order to
better delineate the advantages of the vectors developed here.
For this reason, some of the control groups display little or no sig-
nificant activity.
As a result of these data, it was determined to pursue TRIF
expression in combination with deglycosylation.
Combining Deglycosylation with TRIF Expression
Because ablation of TLR2 activation may reinforce the immuno-
therapeutic effects of TRIF expression, we sought to combine
the two approaches into a single vector. In initial studies, TK-
TRIF virus was deglycosylated as before (dgTK-TRIF), and the
anti-viral immune response elicited in mice was compared to
TK, dgTK, and TK-TRIF (Figures 5A and 5B). It was found268 Cell Reports 15, 264–273, April 12, 2016that dgTK-TRIF demonstrated a profound switch from Th2 to
Th1 immunity as seen with significantly enhanced anti-viral
CTL response and significantly reduced anti-viral neutralizing
antibody titer. Further, when anti-tumor CTL response was
determined in tumor-bearing mice, it was seen that only dgTK-
TRIF displayed significantly greater induction of anti-tumor
CTL response relative to TK virus (Figure 5C). This capacity
to switch the type of immune response raised by a viral vector
has the potential to significantly enhance the therapeutic activity
of multiple therapies, including different oncolytic vectors, or for
other vaccine approaches.
When viral gene expression from the tumor was followed after
systemic delivery to Renca tumors in vivo, it was seen that,
although deglycosylation of TK-TRIF did again result in
increased viral gene expression in the tumor (relative to TK-
TRIF alone), this was not sufficient to restore replication to the
levels of the parental vector (TK; Figure 5D). However, the
reduced replication of dgTK-TRIF relative to TK also provides
a significant safety advantage. Viral treatments in naive animals
(Figure 5E) demonstrated that dgTK-TRIF treatment resulted in
only minor and transient weight loss that was significantly less
than seen with the TK virus. Alternatively, the induction of
high numbers of CTL may raise concerns of auto-immunity.
This was also examined, and no induction of anti-ssDNA
Figure 5. Combination of Envelope Deglyco-
sylation and Mouse TRIF Expression Boosts
Anti-tumor Cellular Responses and En-
hances Safety
(A) Cellular immune response to vaccinia virus
evaluated by IFN-g ELISpot assay. At day 7, post-
virus administration spleens were harvested from
mice injected intravenously with 1 3 108 PFUs of
indicated viruses or PBS (Balb/c mice bearing
Renca tumors) and evaluated for the amount of
CTLs recognizing vaccinia virus. Values of individ-
ual mice and means ± SEM are depicted.
(B) Serum-neutralizing antibody titers. A neutral-
izing assay was performed to determine circulating
anti-vaccinia antibody levels for mice injected with
1 3 108 PFUs of TK, dgTK, TK-TRIF, or dgTK-
TRIF. Nabs titers were determined by the highest
dilution of serum that resulted in at least 50% inhi-
bition of cell-killing capacity. Values of individual
mice and means ± SEM are plotted.
(C) CTL response was measured as in (A), except
ELIPSOT was performed against Renca cell lysate.
(D) Viral gene expression in vivo after dgTK-TRIF
administration. Renca tumors were implanted
in Balb/c mice, and mice were injected with PBS or
1 3 108 PFUs of TK, TK-TRIF, or dgTK-TRIF
through the tail vein. Viral luciferase expression
from within the tumors was measured at indicated
time points. n = 12–14 mice/group + SE.
(E) Body weight change after intravenous viral
administration. Balb/c mice were injected intrave-
nously with 1 3 108 PFUs per mouse of TK, TK-
TRIF, or dgTK-TRIF. PBS administration was used
in the control group. TK-injected mice presented
more than 10% reduction in body weight at day 6
after virus injection, whereas TK-TRIF- and dgTK-
TRIF-injected mice presented a similar weight
profile as those injected with PBS.antibodies or pathology in normal tissues was seen (Figure S6),
indicating dgTK-TRIF did not cause auto-immunity.
Critically, dgTK-TRIF displayed significantly enhanced thera-
peutic activity over either the dgTK or TK-TRIF vectors in
both the Renca and the MC38 tumor models (again after a single
intravenous [i.v.] treatment; Figure 6A). Because JX-594 (Pexa-
Vec) represents the leading clinical oncolytic vaccinia and has
reached primary endpoints in randomized testing, the therapeu-
tic effects of dgTK-TRIF were compared to TK-mGMCSF
(mouse equivalent of JX-594; Pexa-Vec) in a panel of four
different mouse tumor models (Figure 6B). dgTK-TRIF demon-
strated significantly enhanced therapeutic activity in all models
examined, meaning that dgTK-TRIF demonstrates both in-
creased safety and therapeutic activity relative to the most-
promising current clinical oncolytic vaccinia strain.
Repeat Systemic Delivery of dgTK-TRIF
One critical limitation with oncolytic virotherapy is the reduced
capability to repeatedly systemically deliver the virus to the tu-
mor once an anti-viral immune response has been raised. In
initial testing, it was observed that deglycosylation (dgTK) pro-
tected the viral particle from neutralizing antibody raised against
parental vaccinia virus (Figure 7A). Because progeny virus pro-duced after initial delivery of a deglycosylated virus will be nor-
mally glycosylated, neutralizing antibody raised after treatment
with dgTK will primarily target the fully glycosylated form.
Furthermore, because dgTK-TRIF raises a primarily CTL immune
response, with reduced levels of anti-viral neutralizing antibody,
this vector should have even further enhanced capacity for
repeated systemic delivery to the tumor. This was tested through
initial systemic delivery of TK or dgTK-TRIF, followed by a sub-
sequent delivery (7 days later) of the same viruses. This trans-
lated into further increased therapeutic potential. Whereas two
systemic treatments with TK virus (7 days apart) resulted in
no additional therapeutic benefit relative to a single delivery,
repeat cycles of dgTK-TRIF further and significantly increased
therapeutic activity, resulting in seven of ten complete responses
in the aggressive mouse tumor model used (Figure 7B).
DISCUSSION
Although some advances have been made in the treatment
of cancer over the last 20 years, most therapeutic platforms pri-
marily aim to control the disease rather than achieving durable
long-term cures. However, the recent success of several immu-
notherapies, including blockade of immune checkpoint inhibitorsCell Reports 15, 264–273, April 12, 2016 269
Figure 6. In Vivo Anti-tumor Activity in
Different Models
(A) Balb/c-bearing Renca (left) or C57/BL6-bearing
MC38 (right) tumors were treated with a single
intravenous dose of indicated viruses (1 3 108
PFUs/mouse). Tumor growth was followed by
caliper measurements. Means of 12–15 mice per
group + SE are depicted.
(B) dgTK-TRIF improves anti-tumor activity com-
pared to TK-mGMCSF. Immunocompetent mice
harboring Renca, MC38, Pan02, or 4T1 tumors
were injected intravenously with a dose of 1 3 108
PFUs/mouse of TK-mGMCSF or dgTK-TRIF.
Relative tumor volume after virus administration is
plotted (n = 12–15 mice/group + SE). *p < 0.05
compared with PBS group; Jp < 0.05 compared
with TK-GMCSF group.(Leach et al., 1996; Topalian et al., 2012), has demonstrated the
potential for harnessing the immune response to both clear
minimal residual disease and to maintain long-term immune
surveillance.
Another platform that has begun to recapitulate pre-clinical
success in a clinical setting is that of oncolytic viral therapy, pri-
marily driven by vectors that express GM-CSF to stimulate the
immune response and so create a secondary anti-tumor mech-
anism (Park et al., 2008; Heo et al., 2013). The clinical demon-
stration that the immune response raised by oncolytic viruses
can be critical for their therapeutic success has been coupled
to pre-clinical demonstrations that these therapies can act as
in situ vaccines, cross-priming an adaptive immune response
against relevant tumor antigens as a result of their tumor-selec-
tive replication. This led us to attempt to logically redesign an
oncolytic vaccinia to specifically optimize interactions with the
host’s immune system.
The resulting dgTK-TRIF vector has multiple unique features,
demonstrates significant therapeutic advantages over the cur-
rent leading clinical vaccinia vector (JX-594; Pexa-Vec) in
pre-clinical models, and provides insight into host-pathogen in-
teractions that could be applied to other vaccination ap-
proaches. The fact that dgTK-TRIF displays greatly increased
anti-tumor effects despite reduced directly ‘‘oncolytic’’ activity270 Cell Reports 15, 264–273, April 12, 2016also means that it might be better consid-
ered as founding a class of therapies,
immuno-oncolytic vectors.
The stripping of sugars from the viral
particle provides a unique opportunity to
delay immune activation and influence
the immune response pathways before
the vector has even reached a target
cell. Our previous studies have demon-
strated that vaccinia binding to TLR2
leads to rapid STAT3 phosphorylation
and increased neutralizing antibody pro-
duction (O’Gorman et al., 2010). We
have therefore altered the viral particle
itself in order to influence the type of
immune response raised.In addition, combining this reduction in TLR2 (MyD88-depen-
dent) pathway activation with TRIF expression resulted in a clear
switching of the polarity of the immune response from a Th2 to a
primarily Th1 arm. Through manipulation of TLR-signaling path-
ways, we have demonstrated such a switch in the immune
response raised against a microbe. The resulting vector not
only demonstrates clear therapeutic benefits over control and
current clinical vectors but also the reduced overall viral replica-
tion and no induction of auto-immunity results in significantly
reduced toxicity, meaning the vector also has a favorable safety
profile.
This switch from a Th2- to a Th1-skewed immune response
coupled with enhanced safety also indicates possible uses of
this vector beyond the field of oncology, as the basis for a safe
and antigen-expressing vaccine for use against a variety of dis-
eases where a primarily CTL response is desired. Vaccinia-
based vaccines are being developed against diverse diseases,
including HIV (Essajee and Kaufman, 2004), Ebola (Geisbert
et al., 2002), and Plasmodium (Ockenhouse et al., 1998) infec-
tions, and modifications described here may generate more-
effective protective immunity.
Finally, because (1) deglycosylation protects the virus against
neutralizing antibody targeting the parental virus; (2) progeny vi-
rus will be fully glycosylated, so anti-viral immunity will primarily
Figure 7. dgTK-TRIF Displays Enhanced Systemic Delivery and
Therapeutic Activity during Repeat Cycles of Treatment
(A) Deglycosylated virus is resistant to anti-vaccinia neutralizing antibody.
1 3 103 PFUs of TK and deglycosylated TK were mixed with limiting
dilutions of VIG (vaccinia immunoglobulin G [IgG]) for 30 min before addition to
a fresh cell layer and luciferase reading taken 24 hr later (uninfected cells and
virus with no VIG were used to define 0% and 100% neutralization).
(B) Enhanced therapeutic activity of repeated delivery of deglycosylated virus.
Mice (BALB/c-bearing Renca tumors) were treated i.v. with 1 3 108 PFUs of
indicated virus. After 7 days,micewere treatedwith a second dose of the same
viruses. Tumors were measured over time (n = 12–15 per group). dgTK-TRIF
displayed significantly enhanced therapeutic activity (p < 0.05) relative to all
other treatment groups from day 10 onward.be raised against the glycosylated form; and (3) dgTK-TRIF pro-
duces significantly less anti-viral antibody as a result of the Th2
to Th1 switch, this vector retains systemic delivery potential
through repeat cycles of treatment. This provides the potential
to overcome one of themajor current limitations of oncolytic viral
therapy, a limited capacity for repeat delivery. In addition, the ca-
pacity to successfully deliver a second dose of therapy, even af-
ter an anti-viral immune response has been raised, creates the
potential for enhancing the immune response raised through
prime-boost effects, something that has traditionally required
the use of multiple serologically distinct viruses to achieve.
Overall, the data clearly demonstrate the potential of opti-
mizing the immune response raised by oncolytic viral vectors
as a means to enhance therapeutic activity, and we believe
this will form the basis of a powerful cancer treatment approach.
The dgTK-TRIF vector described here represents a promising
cancer treatment approach that will be translated into a clinical
setting.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
HeLa (human cervix adenocarcinoma), Bsc-1 (green monkey normal kidney
cells), 143B (human osteosarcoma), CV-1 (green monkey kidney fibroblasts),
Renca (murine renal adenocarcinoma), Pan02 (murine pancreatic cancer),and 4T1 (murine breast cancer) cell lines were obtained from the American
Type Culture Collection. 293-mTLR2 cells were purchased from InvivoGen.
MC38 (murine colon adenocarcinoma) and MEFs cell lines were, respectively,
a kind gift fromDr. David Bartlett and Dr. Robert Sobol (University of Pittsburgh
Cancer Institute). 293-hTLR2 and 293-hTLR2-hTLR6 were a gift from Dr. Sau-
men Sarkar (University of Pittsburgh Cancer Institute). All cell lines were main-
tained in recommended culture media containing 5%–10% fetal bovine serum
and antibiotics at 37C, 5% CO2.
pNiFty (TLR-signaling reporter plasmid-luciferase) was obtained from
InvivoGen and transfected to 293/mTLR2 cells using FuGENE HD transfection
reagent (Promega).
Viruses
Western Reserve (WR) vaccinia strain was obtained from BEI Resources, and
all recombinant vaccinia viruses used or constructed for this work are based
on this strain. TK vaccinia virus and its derivatives (TK-TRIF and TK-DAI)
contain a deletion in the viral thymidine kinase gene (tk) and express the
firefly luciferase gene from the synthetic vaccinia promoter pE/L (Chakrabarti
et al., 1997). Luciferase expression from this promoter allows monitoring of
bioluminescence as an indicator of viral replication (Chen et al., 2013). In
strains TK-TRIF and TK-DAI, murine TRIF (TICAM1) and murine DAI (DLM-
1/ZBP1), respectively, are expressed from the early/late vaccinia promoter
p7.5 and cloned into the locus of the viral thymidine kinase gene (Figure S2A).
Viruses were titered by plaque assay on BSC-1 cell line andmanufactured and
purified as previously described for in vivo use (Sampath et al., 2013).
For deglycosylation of viruses, an enzymatic deglycosylation kit was
used (Glycopro; Prozyme). N-linked and simple O-linked glycans are
removed from the viral envelope using a cocktail of N- and O-glycanases
and sialidase A.
Protein Analysis
To analyze the deglycosylation of vaccinia virus surface proteins, 13 106 PFUs
of WR or dgWR were disrupted by mixing with Laemmli buffer and incubating
at 65C for 10 min. After separation with SDS-PAGE and transfer to a nitrocel-
lulose membrane, membranes were dyed with Coomassie blue for total pro-
tein staining or immunoblotted using an anti-B5R primary antibody (mouse;
BEI Resources) and a polyclonal anti-mouse conjugated with horseradish
peroxidase (HRP) (goat; Thermo Scientific).
For evaluating DAI expression, cell cultures seeded in 6-well plates were in-
fected at an MOI of 5 (PFUs/cell), and 24 hr after infection, whole-cell protein
extracts were obtained by incubation in cell lysis buffer (Cell Signaling Tech-
nology) for 1 hr at 4C. Clarified samples (15 mg/lane) were separated on a
10% SDS-PAGE gel and transferred to a nitrocellulose membrane. Mouse
DAI protein was detected by immunoblotting membranes using a polyclonal
anti-DAI primary antibody (rabbit; Abcam) and a polyclonal anti-rabbit anti-
body conjugated to HRP (goat; Thermo Scientific). A mouse monoclonal
anti-b actin antibody (Santa Cruz Biotechnologies) and a peroxidase-conju-
gated anti-mouse antibody (goat; Thermo Scientific) were used for immuno-
blotting of b-actin as a loading control.
Evaluation of TLR2 activation by vaccinia proteins utilized recombinant pro-
teins expressed in eukaryotic cells provided placed on 293 cell lines trans-
fected to express hTLR2 or hTLR2 and hTLR6 and activation assayed using
the pNiFty plasmid in a luciferase assay; an IRF3 promoter-driven luciferase
was used as a control.
Mouse Models
All animal studies were approved by the University of Pittsburgh Institutional
Animal Care and Use Committee. BALB/c and C57/BL6 female mice
(6–8 weeks old) were purchased from The Jackson Laboratory. For Renca
or MC38 tumor isografts, tumor cell lines were implanted subcutaneously at
5 3 105 cells per mouse into BALB/c or C57/BL6 mice, respectively. For
4T1, a semi-orthotopic model was used with 2 3 105 4T1 cells implanted
into the fat pad of the mammary gland of BALB/c female mice. When tumor
reached50–100mm3, oncolytic vaccinia viruses were administrated intrave-
nously into the tail vein at doses of 1 3 109PFUs/mouse, unless otherwise
stated. Tumor volume was monitored by caliper measurement and was
defined by the equation V(mm3) = p/63W23 L, whereW and L are the widthCell Reports 15, 264–273, April 12, 2016 271
and the length of the tumor, respectively. Data are expressed as tumor size
relative to the beginning of the therapy, which was set as 100%. For Kaplan-
Meier survival curves, endpoint was established at R750 mm3. The survival
curves obtained were compared for the different treatments. Animals whose
tumor size never achieved the threshold were included as right-censored
information.
For the auto-immunity assays, mice were sacrificed 21 days after treatment
and serum collected for determination of anti-single-stranded DNA (ssDNA)
antibody levels and tissues (liver, lung, kidney, and spleen) collected for H&E
analysis.
Bioluminescence Imaging
Viral gene expression was determined through bioluminescence imaging of
luciferase expression both in vitro and in vivo. For cultured cells, 10 ml of
30 mg/ml D-luciferin (GoldBio) was added to 1 ml of culture media. For animal
models, a dose of 4.5 mg of D-luciferin was injected intraperitoneally per
mouse before imaging. An IVIS2000 model (PerkinElmer) was used for the im-
aging, and images were analyzed with LivingImage software (PerkinElmer).
Flow Cytometry
For testing STAT1 and STAT3 phosphorylation in splenocytes, spleens were
harvested from C57/BL6mice 1 hr after injection of indicated viruses and sple-
nocytes were isolated, fixated in 1.6% paraformaldehyde (PFA), and permea-
bilized with methanol. Two-color intracellular immunostaining analyses were
performed using a LSRFortessa Flow Cytometer (BD Biosciences). Spleno-
cytes were stained using PacificBlue anti-mouse pSTAT1 and Alexa Fluor
647 anti-mouse pSTAT3 antibodies (BD Biosciences).
For evaluation of immune populations in tumors, tumors were harvested
from mice treated as indicated and mechanically disaggregated and digested
with triple-enzyme mixture (collagenase type IV, DNase type IV, and hyaluron-
idase type V; Sigma-Aldrich). Four-color cell surface immunostaining analyses
were performed using a Gallios Flow Cytometer (Beckman Coulter Genomics).
Tumor-disaggregated cells were stained using phycoerythrin (PE)-Cy7 anti-
mouse CD3 (BD Biosciences), fluorescein isothiocyanate (FITC) anti-mouse
CD4, PerCP-Cy5.5 anti-mouse CD8, and PE anti-mouse CD25 (eBioscience).
For apoptosis/necrosis evaluation of cell lines, cells were infected with an
MOI of 1with indicated viruses and stained using an Annexin V-FITCApoptosis
Detection Kit (Abcam) 48 hr after infection. Analyses were performed using an
Accuri C6 Flow Cytometer (BD Biosciences).
ELISAs
Different ELISA kits were used for determining protein concentrations in super-
natant, cell extracts, or nuclear extracts of cells infected at an MOI of 1 (PFU/
cell) with indicated viruses. Mouse TRIF, HMGB1, and IRF3 ELISA kits were
purchased from Antibodies-online, and mouse NFkB pathway activation
ELISA kit and HSP-70 ELISA kit were purchased from eBioscience and
Abcam, respectively. Mouse ssDNA ELISA was purchased from Alpha
Diagnostics.
For mouse IFN-g concentrations in tumor lysates, an IFN-g ELISA kit (R&D
Systems) was used. Tumors harvested from mice treated as indicated were
homogenized using Lysing Matrix D tubes and a FastPrep-24 instrument
(MP Biomedicals).
Luminex
Evaluation of the concentration of cytokines and chemokines in cell culture
supernatants and tumor lysates by Luminex assay was performed by The
Luminex Core Facility of The University of Pittsburgh Cancer Institute. For
cell culture supernatants, a Miliplex Mouse Cytokine Panel (5-plex) Kit from
Millipore and a Mouse 2-plex assay Kit from Panomics were used. For tumor
lysates, a Cytokine Mouse 20-plex Panel Kit from Invitrogen was used for
determining concentrations in tumors harvested at day 4 after vaccinia virus
administration. Tumors were homogenized using Lysing Matrix D tubes and
a FastPrep-24 instrument, as before indicated.
Viral Production and Cytotoxicity Assays
2 3 105 cells were seeded in 24-well plates and infected at an MOI of 1 (PFU/
cell) with indicated vaccinia viruses. Four hours after infection, cultures were272 Cell Reports 15, 264–273, April 12, 2016washed twice with PBS and incubated in fresh virus-free medium. At indicated
time points after infection, cultures were harvested and frozen-thawed three
times to obtain the cell extract (CE). Viral titers were determined by plaque
assay on BSC-1 cells.
Cytotoxicity assay was performed by seeding 2 3 104 cells per well in
96-well plates in DMEM with 5% FBS. Cells were infected with serial dilutions
starting at an MOI of 75, and at day 4 post-infection, plates were washed with
PBS and absorbance was quantified after staining cultures using a nonradio-
active cell proliferation assay kit (Promega). Inhibitory concentration 50%
(IC50) values (PFUs per cell required to produce 50% inhibition) were estimated
from dose-response curves by standard nonlinear regression, using an
adapted Hill equation.
Neutralizing Antibody Assay
Antibody-containing serum was obtained from mice treated as indicated at
day 14 after virus injection and incubated for 30 min at 56C to inactivate
the complement. Serial dilutions (in triplicate) of the serum, starting at 1/20,
were used to neutralize 1,000 PFUs of TK vaccinia virus. 2 3 104 HeLa cells
were plated per well in 96-well and infected with serum-virus mix. At day 4
post-infection, plates were washed with PBS and absorbance was quantified
after staining cultures using a nonradioactive cell proliferation assay kit
(Promega). NAb titer was determined as the lowest dilution able to neutralize
50% of virus cell killing capacity.
IFN-g ELISPOTs
For ELISPOT assays, splenocytes were prepared frommice bearing Renca tu-
mors treated as indicated. Splenocytes were mixed with tumor cells or spleno-
cytes previously infected with UV-inactivated vaccinia virus at 5:1 ratio. Naive
splenocytes from each mouse were used as control. 96-well membrane filter
plates (EMD Millipore) coated with 15 mg/ml of monoclonal anti-mouse IFN-g
antibody AN18 (Mabtech) were used for the assays. Cells were maintained
for 48 hr at 37C, and spots were detected using 1 mg/ml of biotinylated
anti-mouse INF-g antibody R4-6A2-biotin (Mabtech). Plates were developed
using an ABC kit and an AEC substrate kit for peroxidase (Vector Labora-
tories). Specific spots were counted and analyzed using an ImmunoSpot
Analyzer and software (CTL).
Statistical Analysis
Standard Student’s t tests (two-tailed) were used throughout this work, except
for comparison of survival curves, where a log rank was used. In all cases, sig-
nificance was achieved if p < 0.05.
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